Hepatocellular Carcinoma
Conditions
Interventions
radiotherapy effective group vs. radiotherapy invalid group:Nil
Sponsors
Eastern Hepatobiliary Surgery Hospital, Second Military Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Surgical treatment of type I-III hepatocellular carcinoma with portal venous thromboembolism in males or non-pregnant females aged between 20 and 70 years; 2. In the opinion of two senior liver surgeons, the tumor is resectable, and there is no metastasis of other parts outside the liver or invasion of adjacent organs before surgery; 3. ECOG score was 0-1, and the Child with grade A or B liver function was screened; 4. Pathological diagnosis was hepatocellular carcinoma; 5. No significant heart, lung, renal function, HCV, HIV or syphilis infection; 6. All patients should sign informed consent upon inclusion.
Exclusion criteria
Exclusion criteria: 1. Patients who are unable to receive subsequent surgical treatment due to the progression of their disease after receiving neoadjuvant radiotherapy; 2. Patients with intolerant side effects or clinical accidents after receiving neoadjuvant radiotherapy; 3. Unstable angina pectoris, symptomatic congestive heart failure, severe arrhythmia, myocardial infarction in the past 6 months, and prolonged QT interval (> 450ms); 4. Other malignant tumors have appeared within the last 5 years; 5. Patients cannot be followed up or are participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of neoadjuvant radiotherapy;disease-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Computed tomography (CT) images;Pathological image;Overall survival; | — |
Countries
China
Contacts
Public ContactShuqun Cheng
Eastern Hepatobiliary Surgery Hospital, Second Military Medical University
Outcome results
None listed